{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,26]],"date-time":"2026-06-26T12:05:24Z","timestamp":1782475524138,"version":"3.54.5"},"reference-count":83,"publisher":"Hindawi Limited","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1631,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2011,4]]},"DOI":"10.1111\/j.1742-1241.2011.02630.x","type":"journal-article","created":{"date-parts":[[2011,3,15]],"date-time":"2011-03-15T05:20:08Z","timestamp":1300166408000},"page":"379-385","source":"Crossref","is-referenced-by-count":26,"title":["Niacin: the only vitamin that reduces cardiovascular events"],"prefix":"10.1155","volume":"65","author":[{"given":"A. S.","family":"Wierzbicki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"98","published-online":{"date-parts":[[2011,3,15]]},"reference":[{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB1|cit1","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/S0002-9149(02)02436-0","article-title":"The role of high-density lipoprotein (HDL) cholesterol in the prevention and treatment of coronary heart disease: expert group recommendations","volume":"90","author":"Sacks","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB2|cit2","doi-asserted-by":"crossref","first-page":"19L","DOI":"10.1016\/S0002-9149(00)01464-8","article-title":"High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High--Density Lipoprotein Intervention Trial","volume":"86","author":"Boden","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB3|cit3","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/j.1742-1241.2007.01509.x","article-title":"HDL-c is a powerful lipid predictor of cardiovascular diseases","volume":"61","author":"Bruckert","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB4|cit4","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/j.jacc.2004.10.031","article-title":"Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials","volume":"45","author":"Birjmohun","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB5|cit5","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1111\/j.1742-1241.2006.01124.x","article-title":"Prevalence of low HDL-cholesterol in patients with cardiovascular risk factors: The ECHOS (Etude du Cholesterol HDL en Observationnel) French Survey","volume":"60","author":"Farnier","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB6|cit6","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1016\/S0140-6736(10)61350-5","article-title":"Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials","volume":"376","author":"Baigent","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB7|cit7","doi-asserted-by":"crossref","first-page":"14N","DOI":"10.1016\/S0002-9149(01)02147-6","article-title":"The relative role of low-density lipoprotein cholesterol and high-density lipoprotein cholesterol in coronary artery disease: evidence from large-scale statin and fibrate trials","volume":"88","author":"Sacks","year":"2001","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB8|cit8","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1161\/01.CIR.102.16.1893","article-title":"Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the Prospective Pravastatin Pooling Project","volume":"102","author":"Sacks","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB9|cit9","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"366","author":"Baigent","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB10|cit10","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1161\/01.CIR.101.5.477","article-title":"Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force\/Texas Coronary Atherosclerosis Prevention Study (AFCAPS\/TexCAPS)","volume":"101","author":"Gotto","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB11|cit11","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS. Air Force\/Texas Coronary Atherosclerosis Prevention Study","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB12|cit12","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/S0002-9149(03)00530-7","article-title":"Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial)","volume":"92","author":"Jones","year":"2003","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB13|cit13","doi-asserted-by":"crossref","first-page":"2088","DOI":"10.1161\/01.CIR.98.19.2088","article-title":"Mechanism of action of fibrates on lipid and lipoprotein metabolism","volume":"98","author":"Staels","year":"1998","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB14|cit14","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1111\/j.1368-5031.2006.00882.x","article-title":"FIELDS of dreams, fields of tears: a perspective on the fibrate trials","volume":"60","author":"Wierzbicki","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB15|cit15","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB16|cit16","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1056\/NEJM199908053410604","article-title":"Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group","volume":"341","author":"Rubins","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB17|cit17","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial","volume":"366","author":"Keech","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB18|cit18","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1161\/01.CIR.102.1.21","article-title":"Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) study","volume":"102","author":"Bezafibrate Infarction Prevention Study Group","year":"2000","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB19|cit19","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB20|cit20","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/MOL.0b013e32833c1e74","article-title":"Fibrates: no ACCORD on their use in the treatment of dyslipidaemia","volume":"21","author":"Wierzbicki","year":"2010","journal-title":"Curr Opin Lipidol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB21|cit21","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ahj.2007.07.011","article-title":"The role of fibrates in the prevention of cardiovascular disease--a pooled meta-analysis of long-term randomized placebo-controlled clinical trials","volume":"154","author":"Saha","year":"2007","journal-title":"Am Heart J"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB22|cit22","doi-asserted-by":"crossref","first-page":"1875","DOI":"10.1016\/S0140-6736(10)60656-3","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"Jun","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB23|cit23","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1111\/j.1365-2796.2005.01528.x","article-title":"Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review","volume":"258","author":"Carlson","year":"2005","journal-title":"J Intern Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB24|cit24","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1185\/030079904125004402","article-title":"Raising high-density lipoprotein cholesterol with reduction of cardiovascular risk: the role of nicotinic acid--a position paper developed by the European Consensus Panel on HDL-C","volume":"20","author":"Chapman","year":"2004","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB25|cit25","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1111\/j.1742-1241.2010.02620.x","article-title":"Extended release niacin\/laropiprant: lipid altering consistency across patient sub-groups","volume":"65","author":"Bays","year":"2011","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB26|cit26","doi-asserted-by":"crossref","first-page":"743","DOI":"10.1016\/j.amjcard.2006.04.011","article-title":"Effects of extended-release niacin on lipoprotein particle size, distribution, and inflammatory markers in patients with coronary artery disease","volume":"98","author":"Kuvin","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB27|cit27","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1146\/annurev.pharmtox.48.113006.094746","article-title":"Nicotinic acid: pharmacological effects and mechanisms of action","volume":"48","author":"Gille","year":"2008","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB28|cit28","doi-asserted-by":"crossref","first-page":"2727","DOI":"10.1210\/jc.2009-2622","article-title":"Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease","volume":"95","author":"Fabbrini","year":"2010","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB29|cit29","doi-asserted-by":"crossref","first-page":"1672","DOI":"10.1161\/ATVBAHA.108.164541","article-title":"Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins","volume":"28","author":"Lamon-Fava","year":"2008","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB30|cit30","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1038\/nm824","article-title":"PUMA-G and HM74 are receptors for nicotinic acid and mediate its anti-lipolytic effect","volume":"9","author":"Tunaru","year":"2003","journal-title":"Nat Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB31|cit31","doi-asserted-by":"crossref","first-page":"1844","DOI":"10.1124\/mol.106.030833","article-title":"Nicotinic acid-induced flushing is mediated by activation of epidermal langerhans cells","volume":"70","author":"Benyo","year":"2006","journal-title":"Mol Pharmacol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB32|cit32","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.bcp.2005.11.019","article-title":"Niacin induces PPARgamma expression and transcriptional activation in macrophages via HM74 and HM74a-mediated induction of prostaglandin synthesis pathways","volume":"71","author":"Knowles","year":"2006","journal-title":"Biochem Pharmacol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB33|cit33","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.jacl.2008.08.445","article-title":"Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans","volume":"2","author":"Lai","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB34|cit34","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1111\/j.1365-2796.1991.tb00466.x","article-title":"A comparison between nicotinic acid and acipimox in hypertriglyceridaemia--effects on serum lipids, lipoproteins, glucose tolerance and tolerability","volume":"230","author":"Tornvall","year":"1991","journal-title":"J Intern Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB35|cit35","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0026-0495(03)00030-1","article-title":"Nicotinic acid-induced insulin resistance is related to increased circulating fatty acids and fat oxidation but not muscle lipid content","volume":"52","author":"Poynten","year":"2003","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB36|cit36","doi-asserted-by":"crossref","first-page":"1835","DOI":"10.1194\/jlr.M300403-JLR200","article-title":"Niacin noncompetitively inhibits DGAT2 but not DGAT1 activity in HepG2 cells","volume":"45","author":"Ganji","year":"2004","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB37|cit37","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1124\/jpet.110.167478","article-title":"Nicotinic acid decreases apolipoprotein B100-containing lipoprotein levels by reducing hepatic very low density lipoprotein secretion through a possible diacylglycerol acyltransferase 2 inhibition in obese dogs","volume":"334","author":"Le","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB38|cit38","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1016\/j.cmet.2010.09.001","article-title":"Regulation of hepatic ApoC3 expression by PGC-1beta mediates hypolipidemic effect of nicotinic acid","volume":"12","author":"Hernandez","year":"2010","journal-title":"Cell Metab"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB39|cit39","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1194\/jlr.M700426-JLR200","article-title":"Niacin inhibits surface expression of ATP synthase beta chain in hepG2 cells: implications for raising HDL","volume":"49","author":"Zhang","year":"2008","journal-title":"J Lipid Res"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB40|cit40","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.atherosclerosis.2009.12.023","article-title":"Meta-analysis of the effect of nicotinic acid alone or in combination on cardiovascular events and atherosclerosis","volume":"210","author":"Bruckert","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB41|cit41","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1016\/j.thromres.2008.06.022","article-title":"Cholesterylestertransfer protein inhibition and endothelial function in type II hyperlipidemia","volume":"123","author":"Hermann","year":"2009","journal-title":"Thromb Res"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB42|cit42","doi-asserted-by":"crossref","first-page":"1942","DOI":"10.1111\/j.1742-1241.2007.01597.x","article-title":"The effects of extended-release niacin on carotid intimal media thickness, endothelial function and inflammatory markers in patients with the metabolic syndrome","volume":"61","author":"Thoenes","year":"2007","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB43|cit43","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1016\/j.atherosclerosis.2008.08.003","article-title":"Effects of oral niacin on endothelial dysfunction in patients with coronary artery disease: results of the randomized, double-blind, placebo-controlled INEF study","volume":"204","author":"Warnholtz","year":"2009","journal-title":"Atherosclerosis"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB44|cit44","doi-asserted-by":"crossref","first-page":"2190","DOI":"10.1016\/j.jacc.2008.09.049","article-title":"Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus","volume":"52","author":"Hiukka","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB45|cit45","doi-asserted-by":"crossref","first-page":"3512","DOI":"10.1161\/01.CIR.0000148955.19792.8D","article-title":"Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins","volume":"110","author":"Taylor","year":"2004","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB46|cit46","doi-asserted-by":"crossref","first-page":"2243","DOI":"10.1185\/030079906X148508","article-title":"The effect of 24\u2003months of combination statin and extended-release niacin on carotid intima-media thickness: ARBITER 3","volume":"22","author":"Taylor","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB47|cit47","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB48|cit48","doi-asserted-by":"crossref","first-page":"2721","DOI":"10.1016\/j.jacc.2010.03.017","article-title":"The ARBITER 6-HALTS Trial (Arterial Biology for the Investigation of the Treatment Effects of Reducing Cholesterol 6-HDL and LDL Treatment Strategies in Atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration","volume":"55","author":"Villines","year":"2010","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB49|cit49","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB50|cit50","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1016\/S0828-282X(09)70136-9","article-title":"A multicentre, randomized, double-blind placebo-controlled trial evaluating rosiglitazone for the prevention of atherosclerosis progression after coronary artery bypass graft surgery in patients with type 2 diabetes. Design and rationale of the VeIn-Coronary aTherOsclerosis and Rosiglitazone after bypass surgerY (VICTORY) trial","volume":"25","author":"Bertrand","year":"2009","journal-title":"Can J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB51|cit51","unstructured":"Brilakis ES Effect of Extended-Release Niacin on Saphenous Vein Graft Atherosclerosis http:\/\/www.ClinicalTrials.gov\/show\/NCT01221402"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB52|cit52","doi-asserted-by":"crossref","first-page":"1279","DOI":"10.1016\/S0140-6736(05)67528-9","article-title":"Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial","volume":"366","author":"Dormandy","year":"2005","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB53|cit53","doi-asserted-by":"crossref","first-page":"155","DOI":"10.2337\/diacare.27.1.155","article-title":"XENical in the prevention of diabetes in obese subjects (XENDOS) study: a randomized study of orlistat as an adjunct to lifestyle changes for the prevention of type 2 diabetes in obese patients","volume":"27","author":"Torgerson","year":"2004","journal-title":"Diabetes Care"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB54|cit54","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.231.4.360","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","author":"The Coronary Drug Project Research Group","year":"1975","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB55|cit55","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1001\/jama.226.6.652","article-title":"The Coronary Drug Project: findings leading to discontinuation of the 2.5-mg\/day estrogen group","volume":"226","author":"Coronary Drug Project Investigators","year":"1973","journal-title":"J Am Med Assoc"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB56|cit56","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB57|cit57","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.amjcard.2004.09.013","article-title":"Benefits of niacin by glycemic status in patients with healed myocardial infarction (from the Coronary Drug Project)","volume":"95","author":"Canner","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB58|cit58","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB59|cit59","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1161\/01.CIR.85.1.37","article-title":"Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment","volume":"85","author":"Manninen","year":"1992","journal-title":"Circulation"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB60|cit60","unstructured":"National Heart Lung and Blood Institute (NHLBI) Niacin Plus Statin to Prevent Vascular Events: AIM-HIGH http:\/\/www.clinicaltrials.gov\/ct\/show\/NCT00120289"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB61|cit61","unstructured":"HPS2-THRIVE investigators A Randomized Trial of the Long-Term Clinical Effects of Raising HDL Cholesterol with Extended Release Niacin\/Laropiprant. Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) http:\/\/clinicaltrials.gov\/ct2\/show\/NCT00461630"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB62|cit62","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1111\/j.1368-5031.2006.00957.x","article-title":"Clinical evidence for use of acetyl salicylic acid in control of flushing related to nicotinic acid treatment","volume":"60","author":"Oberwittler","year":"2006","journal-title":"Int J Clin Pract"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB63|cit63","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1093\/schbul\/sbm153","article-title":"Impaired flush response to niacin skin patch among schizophrenia patients and their nonpsychotic relatives: the effect of genetic loading","volume":"35","author":"Chang","year":"2009","journal-title":"Schizophr Bull"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB64|cit64","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/0090-6980(89)90088-9","article-title":"Release of markedly increased quantities of prostaglandin D2 in vivo in humans following the administration of nicotinic acid","volume":"38","author":"Morrow","year":"1989","journal-title":"Prostaglandins"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB65|cit65","doi-asserted-by":"crossref","first-page":"2910","DOI":"10.1172\/JCI42273","article-title":"Nicotinic acid- and monomethyl fumarate-induced flushing involves GPR109A expressed by keratinocytes and COX-2-dependent prostanoid formation in mice","volume":"120","author":"Hanson","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB66|cit66","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.maturitas.2009.08.011","article-title":"Calcitonin gene-related peptide, adrenomedullin and flushing","volume":"64","author":"Hay","year":"2009","journal-title":"Maturitas"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB67|cit67","doi-asserted-by":"crossref","first-page":"672","DOI":"10.1001\/jama.271.9.672","article-title":"A comparison of the efficacy and toxic effects of sustained- vs immediate-release niacin in hypercholesterolemic patients","volume":"271","author":"McKenney","year":"1994","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB68|cit68","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/0026-0495(92)90170-F","article-title":"Differences in metabolism of time-release and unmodified nicotinic acid: explanation of the differences in hypolipidemic action?","volume":"41","author":"Stern","year":"1992","journal-title":"Metabolism"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB69|cit69","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jacl.2007.04.003","article-title":"The role of nicotinic acid metabolites in flushing and hepatotoxicity","volume":"1","author":"Stern","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB70|cit70","doi-asserted-by":"crossref","first-page":"6682","DOI":"10.1073\/pnas.0601574103","article-title":"Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans","volume":"103","author":"Cheng","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB71|cit71","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1016\/j.amjcard.2009.02.047","article-title":"Flushing profile of extended-release niacin\/laropiprant versus gradually titrated niacin extended-release in patients with dyslipidemia with and without ischemic cardiovascular disease","volume":"104","author":"Maccubbin","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB72|cit72","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1016\/j.ejpain.2008.09.001","article-title":"Comparison of nociceptive behavior in prostaglandin E, F, D, prostacyclin and thromboxane receptor knockout mice","volume":"13","author":"Popp","year":"2009","journal-title":"Eur J Pain"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB73|cit73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.clinthera.2009.01.010","article-title":"Blood pressure-lowering effects of extended-release niacin alone and extended-release niacin\/laropiprant combination: a post hoc analysis of a 24-week, placebo-controlled trial in dyslipidemic patients","volume":"31","author":"Bays","year":"2009","journal-title":"Clin Ther"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB74|cit74","doi-asserted-by":"crossref","first-page":"2032","DOI":"10.1093\/eurheartj\/ehi310","article-title":"Effect of bezafibrate on incidence of type 2 diabetes mellitus in obese patients","volume":"26","author":"Tenenbaum","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB75|cit75","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(09)61965-6","article-title":"Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials","volume":"375","author":"Sattar","year":"2010","journal-title":"Lancet"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB76|cit76","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1185\/030079906X89766","article-title":"Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study","volume":"22","author":"Vogt","year":"2006","journal-title":"Curr Med Res Opin"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB77|cit77","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1001\/jama.284.10.1263","article-title":"Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial Disease Multiple Intervention Trial","volume":"284","author":"Elam","year":"2000","journal-title":"JAMA"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB78|cit78","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1161\/01.ATV.0000161928.16334.dd","article-title":"Effects of cholesteryl ester transfer protein inhibition on high-density lipoprotein subspecies, apolipoprotein A-I metabolism, and fecal sterol excretion","volume":"25","author":"Brousseau","year":"2005","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB79|cit79","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1056\/NEJMoa0706628","article-title":"Effects of torcetrapib in patients at high risk for coronary events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB80|cit80","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1038\/bjp.2008.229","article-title":"Torcetrapib-induced blood pressure elevation is independent of CETP inhibition and is accompanied by increased circulating levels of aldosterone","volume":"154","author":"Forrest","year":"2008","journal-title":"Br J Pharmacol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB81|cit81","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.amjcard.2009.02.061","article-title":"Safety and tolerability of dalcetrapib","volume":"104","author":"Stein","year":"2009","journal-title":"Am J Cardiol"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB82|cit82","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1056\/NEJMoa1009744","article-title":"Safety of anacetrapib in patients with or at high risk for coronary heart disease","volume":"363","author":"Cannon","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1742-1241.2011.02630.x-BIB83|cit83","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1039\/b902356a","article-title":"Systems biology approaches and pathway tools for investigating cardiovascular disease","volume":"5","author":"Wheelock","year":"2009","journal-title":"Mol Biosyst"}],"container-title":["International Journal of Clinical Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1742-1241.2011.02630.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/onlinelibrary.wiley.com\/wol1\/doi\/10.1111\/j.1742-1241.2011.02630.x\/fullpdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,28]],"date-time":"2022-01-28T06:07:52Z","timestamp":1643350072000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1742-1241.2011.02630.x"}},"subtitle":["Editorials"],"short-title":[],"issued":{"date-parts":[[2011,3,15]]},"references-count":83,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2011,4]]}},"URL":"https:\/\/doi.org\/10.1111\/j.1742-1241.2011.02630.x","relation":{},"ISSN":["1368-5031"],"issn-type":[{"value":"1368-5031","type":"print"}],"subject":[],"published":{"date-parts":[[2011,3,15]]}}}